Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Wave Life Sciences (WVE) EBITDA Margin (2016 - 2025)

Wave Life Sciences (WVE) has disclosed EBITDA Margin for 11 consecutive years, with 579.68% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, EBITDA Margin fell 41207.0% year-over-year to 579.68%, compared with a TTM value of 1143.37% through Dec 2025, down 84196.0%, and an annual FY2025 reading of 478.31%, down 38861.0% over the prior year.
  • EBITDA Margin was 579.68% for Q2 2025 at Wave Life Sciences, down from 510.3% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 14.67% in Q3 2023 and bottomed at 13712.28% in Q3 2022.
  • Average EBITDA Margin over 5 years is 2379.74%, with a median of 510.3% recorded in 2025.
  • The sharpest move saw EBITDA Margin plummeted -1369515bps in 2022, then surged 1372695bps in 2023.
  • Year by year, EBITDA Margin stood at 1975.18% in 2021, then plummeted by -78bps to 3520.18% in 2022, then surged by 98bps to 55.75% in 2023, then plummeted by -201bps to 167.6% in 2024, then plummeted by -246bps to 579.68% in 2025.
  • Business Quant data shows EBITDA Margin for WVE at 579.68% in Q2 2025, 510.3% in Q1 2025, and 167.6% in Q2 2024.